Skip to main content

Articles

Multiple Myeloma, Conference Highlights ASCO, Oncology

New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

FDA Approvals, Leukemia, Lymphoma, Conference Highlights ASCO, Oncology

Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma

Cholangiocarcinoma, FDA Approvals, Conference Highlights ASCO, Oncology

Truseltiq Second Targeted Therapy Approved for Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

FDA Approvals, Multiple Myeloma, Conference Highlights ASCO, Oncology

FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma

FDA Approvals, Conference Highlights ASCO

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

FDA Approvals, Conference Highlights ASCO

Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma

FDA Approvals, Urothelial Cancer, Conference Highlights ASCO, Oncology

Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer

Melanoma, Conference Highlights ASCO, Oncology

Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma

Wayne Kuznar

Prostate Cancer, Conference Highlights ASCO

¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer

Phoebe Starr

Conference Highlights ASCO

Early Phase 3 Results Show Survival Benefit with Nivolumab-Based Regimens in Advanced Esophageal Squamous-Cell Cancer

Wayne Kuznar

Page 21 of 244
Results 201 - 210 of 2440